Generic Oncology Sterile Injectable Market To Surpass US$ 27,543.1 Million By 2027 - Coherent Market Insights

1. GENERIC ONCOLOGY STERILE INJECTABLE MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Generic Oncology Sterile Injectable - Overview Generic Oncology Sterile Injectable Market – Insights Generic oncology sterile injectables Market are biologics that have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different. Manufacturers of generic sterile injectables have to adhere to regulations by the U.S. Food and Drug Administration (FDA) for the development of these injectables, which are equivalent to that of branded counterparts. These generic oncology sterile injectables are used for the treatment of various types of cancer including breast, prostate, colorectal, melanoma, lung, and bronchus. These injectables are available at low prices and therefore, are widely preferred over branded drugs. Furthermore, R&D for generic drugs require less capital, which increase competition to enter into generic oncology sterile injectable market as soon as the patent for branded injectables expire. However, the emergence of biosimilars have increased in the recent past. After Europe, increasing number of biosimilars are approved in the U.S. market. This is expected to drive growth of the generic oncology sterile injectable market growth during the forecast period. The global generic oncology sterile injectable market size is estimated to be valued at US$ 11,496.7 million in 2019 and is expected to witness a CAGR of 11.5% over the forecast period (2019 – 2027). Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/generic- oncology-sterile-injectables-market-562 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Increasing launches of drugs is expected to drive growth of the global generic oncology sterile injectable market Manufacturers in the U.S. are focusing on launching new products to offer low cost treatment to patients. For instance, in November, 2017, Mylan N.V. launched Clofarabine Injection (20 mg/20 mL (1 mg/mL) Single-Dose Vials) following the U.S. Food and Drug Administration approval in the U.S. market. Clofarabine is a generic version of Genzyme's Clolar, which is used for the treatment of refractory acute lymphoblastic leukemia in patients aged 1 year to 21 years. Global Generic Oncology Sterile Injectable Market – Restraints Stringent rules and regulations for manufacturing of sterile oncology injectables, high quality and care required during manufacturing, challenges in storage, packaging, and distribution of oncology sterile injectable are factors restraining the global generic oncology sterile injectable market growth. Request a Sample copy of this reports :https://www.coherentmarketinsights.com/insight/request-sample/562 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Global Generic Oncology Sterile Injectable Market - Regional Insights On the basis of region, the global generic oncology sterile injectable market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the global generic oncology sterile injectable market, owing to increasing launches of products in the U.S. For instance, in September 2019, Mylan N.V. launched Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex Injection, for the treatment of advanced breast cancer in the U.S. Asia Pacific is the fastest growing region in the global generic oncology sterile injectable market, owing to increasing initiatives taken by key players in this region. For instance, in 2017, Alembic Pharmaceutical Limited launched manufacturing facility in India to manufacture generic oncology products for international market. Key players operating in the global generic oncology sterile injectable market include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/562 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved